Experimental drug may offer more protection from RSV

12/16/2009 | Medscape (free registration)

Researchers reported in Pediatrics that the investigational drug motavizumab may protect children at high risk for respiratory syncytial virus better than palivizumab. Study data showed motavizumab reduced the risk of RSV hospitalization by 26% and the risk of outpatient RSV-related lower respiratory tract infection by 50%.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN